Business Results for Fiscal 2022
May 10, 2023
TSUMURA & CO.
Agenda
01 |
02 |
Business Results for Fiscal 2022 and Earnings Forecast for Fiscal 2023
Outlook for China Business
2
Business Results for Fiscal 2022 and Earnings Forecast for Fiscal 2023
Director, and CFO
Muneki Handa
Agenda
01
FY 2022 Business Results Overview
4
Roadmap for the Realization of the TSUMURA VISION
"Cho-WA" 2031
1st stage
FY2022-2024
-Germination-
2nd stage
FY2025-2027
-Growth-
3rd stage
FY2028-2031
-Flowering-
Prescription Kampo
Products
Standardization of Kampo treatments
Personalized Kampo treatments
Over 50% physicians write 10 or more Kampo prescriptions
50% of physicians write basic |
prescriptions in all treatment areas |
R&D
Personalized Kampo
treatmentsResearch Scientific study of pre-
symptomatic diseases
Development
Social
implementation
Formulation | ||
platform | ||
China | ||
Crude drug | ||
Business | platform | |
Research | ||
platform | ||
Traditional Chinese medical products business
Crude drugs, drug pieces and Yakushokudogen products
Traditional Chinese Medicine Research Center
Market
entry
Sales
expansion
Establishment
Build
foundations
Establish brands
Function
expansion
Establish brands
Lead industry development
Evidence-building for traditional
Chinese medical products
Smart factory
Expand scope of
automation
Shift to oversight/management
Realize smart factories
Labor
productivity
Sales
Production
Crude drugs
Sales per MR (Yen/MR)
Physical labor productivity
Personnel expenses per crude drug arranging volume
Double productivity | |
(vs. FY2021) | 5 |